CatalystMarker
Sign in
← board

ZTS

distress 3/10 · well-funded / low risk
$74.48+0%today-52% from 52w high
zoetis.com14,500 employeesFounded 2012Parsippany, NJDrug Manufacturers - Specialty & Generic
Revenue
$2262M
Liquidity
$1941M
Runway
—
Shares 1y
-5%

Price & events

-39.4% over 6M
$71.36$100$130Jan 26Apr 26Jul 2629.9Mrating: HSBC: Buy (2026-07-06)rating: Barclays: Equal-Weight (2026-07-01)rating: TD Cowen: Buy (2026-06-30)rating: Stifel: Hold (2026-06-26)rating: Argus Research: Buy → Hold (2026-05-27)rating: Stifel: Hold (2026-05-22)rating: Citigroup: Buy (2026-05-18)rating: JP Morgan: Overweight (2026-05-08)
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
-2.5%
1W
-2.4%
1M
-35.4%
3M
-39.3%
6M
-50.5%
1Y
-57.5%
2Y
-61.6%
5Y
-52.0%
All

Overview

Market Cap
$31.22B
Enterprise Value
$38.33B
Volume
285.31K
52 Week Range
$71.86 – $157
Total Shares
419.23M
Float Shares
418.38M
Short %
4.29%
% Held by Insiders
0.15%
% Held by Institutions
102.86%
RVOL
0.04x
Beta
0.75

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 419,228,118 · 3 offerings/1y · 1 PIPEs
  • 2025-12-188-Kprivate_placement
  • 2025-08-278-Kmaterial_agreement
  • 2025-08-12424B3offering
  • 2025-08-11424B3offering
  • 2025-08-11FWPoffering
  • 2025-08-05S-3ASRshelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $115 (+54% upside) · 17 analysts
  • 2026-07-06HSBCBuy
  • 2026-07-01BarclaysEqual-Weight
  • 2026-06-30TD CowenBuy
  • 2026-06-26StifelHold
  • 2026-05-27Argus ResearchBuy → Hold
  • 2026-05-22StifelHold

Competitors

  • none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.